Q-omics provides the consensus-scored HCG14 profile across patient tissues and cancer cell-line models. HCG14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HCG14 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HCG14 RNA expression shows 13,371 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where HCG14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG14 survival associations across molecular data types. HCG14 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG14 RNA expression–survival associations across cancer types. High HCG14 expression shows unfavorable associations in KIRC, but favorable associations in BRCA, OV, PAAD, MESO and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HCG14 RNA expression.
This table summarizes HCG14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HCG14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG14 shows lower tumor expression in KIRC, KICH, THCA, LUAD, LUSC and BRCA. The KIRC box plot shows higher HCG14 RNA expression in normal versus tumor tissue (log2 FC = −0.739, t-test p < 0.001).
This table shows molecular features associated with HCG14 in patient tissues and cancer cell lines. In patient samples, HCG14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
